Compare Fidelity National Information Servcs Inc (FIS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs ResMed Inc. — how do they compare? Fidelity National Information Servcs Inc trades at $34.5 (market cap $17.71B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays the higher dividend (5.13%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and ResMed Inc. for 51 Days on average.
| FIS | RMD | |
|---|---|---|
Market Cap | $17.71B | $31.89B |
Volume | 9,047,825 | 618,314 |
Sector | Technology | Health |
52-Week High | $68.57 | $277.88 |
52-Week Low | $32.44 | $182.82 |
Typical Hold Time | 88 Days | 51 Days |
Enterprise Value | $38.22B | $31.24B |
Dividend Yield | 5.13% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal despite beating earnings estimates in two of the last three quarters. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while analyst consensus remains strongly bullish with a $47.15 price target. Recent business developments include multiple core banking platform wins and new embedded banking offerings, signaling growth momentum in financial technology services.
The outlook appears positive given FIS's improving profitability trajectory and strong analyst support, though investors should monitor debt levels and execution risks. With revenue projected to grow to $12.2B in 2026 and net income margin expanding to 27.64%, the stock offers fundamental upside potential if the company can maintain its competitive positioning in banking technology modernization.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
